6:50 PM
 | 
Oct 17, 2007
 |  BC Extra  |  Company News

Partners unveil Erbitux deal for Japan

ImClone (IMCL), Bristol-Myers (BMY) and Merck KGaA (FSE:MRK) agreed to co-develop and co-commercialize Erbitux cetuximab in Japan. The chimeric MAb against the epidermal growth factor (EGF) receptor is...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >